Pfizer Inr 235 East 42nd Street New York. !W 10007-5755 March 25,2008 Steven Reynolds Director U.S. Nuclear Regulatory Commission Division of Nuclear Materials Safety 2443 Warrenville Road, STE 210 Lisle, IL 60532-4352 -Re: Parent Company Guarantee for Pharmacia Corporation (Chesterfield, MO and St. Louis, MO) Dear Mr. Reynolds: I am the Chief Executive Officer of Pfizer Inc. located at 235 East 42"d Street in New York, NY 10017. This letter is in support of this firm's use of the financial test to demonstrate financial assurance, as specified in 10 CFR Part 30. I hereby certify that Pfizer Inc. is currently a going concern, and that it possesses positive tangible net worth in the amount of $23,129,000,000. This firm is required to file a Form 10K with the U.S. Securities and Exchange Commission for the latest fiscal year. The fiscal year of this firm ends on December 3 1. I hereby certify that the content of this letter is true and correct to the best of my knowledge. panof the Board C ief Executive Officer Pfizer lnr 235 East 42nd Street New York, NY 10007-5755 March 25. 2008 Steven Reynolds Director U.S. Nuclear Regulatory Coinmission Division of Nuclear Material Safet) 2443 Warrenville Road STE 2 IO Lisle. IL 60532-4352 -Re: Financial Assurance Demonstration for Pharmacia Corporation (Chesterfield, MO and St. Louis, MO) Dear Mr. Reynolds: I am the chief financial officer of Pfizer Inc., 235 East 42'ld Street, New York. New York 10017, a corporation. This letter is in support of this firm's use of the parent company guarantee financial test to demonstrate financial assurance, as specified in IO CFR Part 30. This firni guarantees, through the parent company guarantee submitted to demonstrate conipl iance under IO CFR Part 30. the decommissioning of the following facilities oisned or operated b) this firm. The current cost estimates or certified amounts for decoininissioning, so guaranteed. are shoil'n for each fac i I ity : U.S. NRC License Name and Address Certified Amount or Numbers of Licensee Address of Licensed Facility Current Cost Estimates 34-32439-0 1 Pharmacia Pharmacia Corporation $I, 125.000 Corporation Mail Zone BB3G 100 Rt. 206 North 700 Chesterfield Parkway West Peapack, NJ 07977 Chesterfield, Missouri 6301 7 I hereby certify that Pfizer Inc. is currently a going concern, and that it possesses positive tangible net north in the amount of $23.1 29,000,000. The fiscal year of this firm ends on December 3 I. The figures for the follo\i ing items marked \iith an asterisk are derived from this firm's independently audited, year-end financial statements and footnotes for the latest completed fiscal year ended December 3 I, 2007, or from the firm's internal accounting records underlying such financial statement. A cop) of this firm's most recent financial statements is enclosed. This firm is required to file a Form 10-K with the U.S. Securities and Exchange Commission for the latest fiscal year. This firm has at least one class of equity securities registered under the Securities Exchange Act of 1934. Alternative 2 1. Current decommissioning cost estimates or certified amounts: a. Decommissioning amounts covered by this parent $1,125,000 colnpany guarantee b. All decommissioning amounts covered by other $19,995,138 NRC or Agreement State parent company guarantees or self-guarantees. c. All amounts covered by parent company guarantees, $1 35,713,646 self-guarantees, or financial tests of other Federal or State agencies (e.g., EPA) TOTAL $156.833,784 2. Current bond rating of most recent unsecured issuance of Rating: Name of Rating this firm. Service AAAIAa 1 Standard & Poor's and Moody's 3. Date of issuance of bond 05/14/07 & 1211 3/07 4. Date of maturity of bond 05/15/17& 12/15/14 *5. Tangible net worth (If any portion of estimates for $23.129,000,000 decommissioning is included in total liabilities on your firm's financial statements, you may add the amount of that portion to this line.) *6. Total assets' in United States (required only if less than $29.5 12,000.000 90 percent of firm's assets are located in the United States) YES NO 7. Is line 5 at least 10 times line I? X *8. Are at least 90 percent of firm's assets located in the United States? If not, X complete line 9. 9. Is line 6 at least 10 times line I? X 10. Is the rating specified on line 2 "A" or better X 1 I. Does the licensee have at least one class of equity securities registered X under the Securities Exchange Act of 1934? I Represents identifiable assets onlj, \ihich includes net accounts & notes receivable. inventories, net fixed assets. goodwill, and net intangibles. 2 1 hereby certify that the content of this letter is true and correct to the best of my knowledge Effective Date: March 25. 2008 Pfizer Inc. Frank A, D'Amelio Senior Vice President and Chief Financial Officer Signature of witness or notary: @weM&* cc: Don Grothe (St. Louis, MO) 3 KPMG LLP Telephone 212 758 9700 345 Park Avenue Fax 212 758 9819 NewYork. NY 10154 Internet www us.kpmg corn Independent Accountants’ Special Report on Confirmation of Letter from Chief Financial Officer The Board of Directors and Management of Pfizer Inc.: We have audited the consolidated financial statements of Pfizer Inc. (“the Company”) for the year ended December 3 1,2007, and have issued our report thereon dated February 29,2008. Our work did not extend from the period of February 29,2008 through the date herein. We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. As audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. The Company acquired Pharmacia Corporation on April 16, 2003. Pfizer Inc has prepared documents to demonstrate its financial responsibility under the United States Nuclear Regulatory Commission’s (“NRCI’) financial assurance regulations, 10 CFR Part 30. This letter is furnished to assist the following licensee in complying with these regulations and should not be used for other purposes: Pharmacia Corporation 100 Rt. 206 North Peapack, NJ 07977 License Nos.: 24-32439-01 We have performed the procedures enumerated below, which were agreed to by management of Pfizer Inc., solely to assist management of the Company in complying with the NRC - Division of Waste Management financial assurance regulations, Title 10, Chapter I of the Code of Federal Regulations, part 30 (“1 0 CFR part 30”) Appendix C, Criteria Relating to the Use of Financial Tests and Self Guarantees for Providing Reasonable Assurance of Funds for Decommissioning, as of and for the year ended December 3 1, 2007. Management of the Company is responsible for Pfizer Inc.’s compliance with those requirements. This agreed-upon procedures engagement was conducted in accordance with attestation standards established by the American Institute KFMG LLF a U S limited Iiabilitv partnership is the U S member iirm of KPMG International a Swiss cooperative of Certified Public Accountants. The sufficiency of these procedures is solely the responsibility of management of the Company. Consequently, we make no representations regarding the sufficiency of the procedures described below either for the purpose for which this report has been requested or for any other purpose. The attached schedule, which was prepared by management of the Company, reconciles the specified financial information furnished in the Company Chief Financial Officer’s (“CFO’s”) letter in response to the regulations with the Company’s audited financial statements (“the Letter”) as of and for the year ended December 3 1, 2007. In connection therewith, we have: 1. Compared the amounts in the column “Per Financial Statements” to the amounts contained in the Company’s audited financial statements for the year ended December 3 1,2007 and found them to be in agreement; 2. Compared the amounts in the column “Per CFO’s Letter” to the amounts set forth in the Letter prepared in response to the NRC’s request and found them to be in agreement; 3. Compared the amounts in the column “Reconciling Items” to the amounts in the Company’s Computron general ledger as of and for the year ended December 3 1, 2007 and found them to be in agreement; and 4. Recomputed the mathematical accuracy of the totals set forth in the attached schedule. We were not engaged to, and did not, conduct an examination, the objective of which would be the expression of an opinion on the specified amounts in the Letter. Accordingly, we do not express such an opinion. Had we performed additional procedures, other matters might have come to our attention that would have been reported to you. This report is intended solely for the information and use of the Board of Directors and management of Pfizer Inc., and is not intended to be and should not be used by anyone other than the Board of Directors and management of Pfizer Inc. March 25,2008 PFIZER INC. Year Ended December 3 I, 2007 Dollar amounts in millions Schedule of Reconciling Amounts Contained in Chief Financial Officer’s Letter with Amounts in Financial Statements Per Line Number Per Financial Reconciling CFO’s in CFO’s Letter Statements Items Letter 5 Total Shareholder’s Equity $65,009 Less: Goodwill ($21,382) Less: Identifiable intangible assets.